Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 491 articles:
HTML format



Single Articles


    March 2023
  1. WEI Z, Luy DD, Tang LW, Deng H, et al
    Gamma Knife radiosurgery for gynecologic metastases to the brain: Analysis of pathology, survival, and tumor control.
    Gynecol Oncol. 2023;172:21-28.
    PubMed     Abstract available


  2. OSANN K, Wenzel L, McKinney C, Wagner L, et al
    Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
    Gynecol Oncol. 2023;171:151-158.
    PubMed     Abstract available


  3. SPENARD E, Geerts W, Lin Y, Gien LT, et al
    Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
    Gynecol Oncol. 2023;172:9-14.
    PubMed     Abstract available


  4. LECHARTIER C, Bernard J, Renaud MC, Plante M, et al
    Robotic-assisted surgery for endometrial cancer is safe in morbidly and extremely morbidly obese patients.
    Gynecol Oncol. 2023;172:15-20.
    PubMed     Abstract available


  5. TEWARI KS, Sill MW, Birrer MJ, Penson RT, et al
    Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study.
    Gynecol Oncol. 2023;171:141-150.
    PubMed     Abstract available


  6. HITCHINS MP, Alvarez R, Zhou L, Aguirre F, et al
    MLH1-methylated endometrial cancer under 60 years of age as the "sentinel" cancer in female carriers of high-risk constitutional MLH1 epimutation.
    Gynecol Oncol. 2023;171:129-140.
    PubMed     Abstract available


  7. BJORNHOLT SM, Sponholtz SE, Mogensen O, Bouchelouche K, et al
    The SENTIREC-endo study - Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer.
    Gynecol Oncol. 2023;171:121-128.
    PubMed     Abstract available


  8. MOOLENAAR LR, van Rangelrooij LE, van Poelgeest MIE, van Beurden M, et al
    Clinical outcomes of pelvic exenteration for gynecologic malignancies.
    Gynecol Oncol. 2023;171:114-120.
    PubMed     Abstract available


  9. FOTOPOULOU C
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
    Gynecol Oncol. 2023;170:A1-A3.
    PubMed    


  10. LEE SS, Karpel HC, Oh C, Smith J, et al
    Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    Gynecol Oncol. 2023;170:234-240.
    PubMed     Abstract available


  11. COLLARINO A, Fuoco V, Garganese G, Pasciuto T, et al
    Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review.
    Gynecol Oncol. 2023;170:153-159.
    PubMed     Abstract available


  12. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Gynecol Oncol. 2023;170:143-152.
    PubMed     Abstract available


  13. LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
    Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
    Gynecol Oncol. 2023;170:93-101.
    PubMed     Abstract available


  14. HAROLD J, Bellone S, Manavell DD, Mutlu L, et al
    Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
    Gynecol Oncol. 2023;170:334.
    PubMed    


  15. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2023;171:106-113.
    PubMed     Abstract available


    February 2023
  16. GADDUCCI A, Multinu F, De Vitis LA, Cosio S, et al
    Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2023;171:95-105.
    PubMed     Abstract available


  17. HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
    The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;171:83-94.
    PubMed     Abstract available


  18. BLANK SV, Huh WK, Bell M, Dilley S, et al
    Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.
    Gynecol Oncol. 2023;171:76-82.
    PubMed     Abstract available


  19. BENBROOK DM, Deng W, Gold MA, Rai R, et al
    Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study.
    Gynecol Oncol. 2023;171:67-75.
    PubMed     Abstract available


  20. VAN KOL KGG, Ebisch RMF, van der Aa M, Wenzel HB, et al
    The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
    Gynecol Oncol. 2023;171:9-14.
    PubMed     Abstract available


  21. TANG H, Fayomi AP, Bai S, Gupta N, et al
    Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.
    Gynecol Oncol. 2023;171:49-58.
    PubMed     Abstract available


  22. LI G, Xu W, Li X, Chen M, et al
    Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.
    Gynecol Oncol. 2023;171:39-48.
    PubMed     Abstract available


  23. ALIMENA S, Fallah P, Stephenson B, Feltmate C, et al
    Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes.
    Gynecol Oncol. 2023;171:31-38.
    PubMed     Abstract available


  24. PRAISS AM, Zhou Q, Iasonos A, Moukarzel L, et al
    Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
    Gynecol Oncol. 2023;171:23-30.
    PubMed     Abstract available


  25. DESSOURCES K, Ferrando L, Zhou QC, Iasonos A, et al
    Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.
    Gynecol Oncol. 2023;171:15-22.
    PubMed     Abstract available


  26. JIANG S, Zhao J, Shi X, Wu H, et al
    Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor.
    Gynecol Oncol. 2023;171:1-8.
    PubMed     Abstract available


  27. O'MALLEY DM, Ledermann JA, Coleman RL
    Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
    Gynecol Oncol. 2023 Feb 9:S0090-8258(23)00049.
    PubMed    


  28. KIM C, Salvo G, Ishikawa M, Chen TC, et al
    The role of postoperative radiation after radical hysterectomy for women with early-stage neuroendocrine carcinoma of the cervix: A meta-analysis.
    Gynecol Oncol. 2023;170:328-332.
    PubMed     Abstract available


  29. LIANG MI, Harrison R, Aviki EM, Esselen KM, et al
    Financial toxicity: A practical review for gynecologic oncology teams to understand and address patient-level financial burdens.
    Gynecol Oncol. 2023;170:317-327.
    PubMed     Abstract available


  30. KISSEL M, Balaya V, Guani B, Magaud L, et al
    Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials.
    Gynecol Oncol. 2023;170:309-316.
    PubMed     Abstract available


  31. HERZOG TJ, Pignata S, Ghamande SA, Rubio MJ, et al
    Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:300-308.
    PubMed     Abstract available


  32. WIESER V, Tsibulak I, Reimer DU, Zeimet AG, et al
    An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
    Gynecol Oncol. 2023;170:290-299.
    PubMed     Abstract available


  33. JAMIESON A, Huvila J, Leung S, Chiu D, et al
    Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.
    Gynecol Oncol. 2023;170:282-289.
    PubMed     Abstract available


  34. JANSEN A, de Jong A, Hoogendam JP, Baeten IGT, et al
    Lymphocele following lymph node dissection in cervical and endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;170:273-281.
    PubMed     Abstract available


  35. KAUR A, Wang S, Kumar A
    Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.
    Gynecol Oncol. 2023;170:266-272.
    PubMed     Abstract available


  36. KOFOED NG, Falconer H, Vanky H, Johansson H, et al
    Survival and chance of reversal after intestinal stoma formation during cytoreductive surgery for advanced ovarian cancer; a population-based cohort study.
    Gynecol Oncol. 2023;170:259-265.
    PubMed     Abstract available


  37. KOEHLER L, Penz LE, John F, Stenzel A, et al
    Functional and psychosocial quality of life in gynecologic Cancer survivors with and without lymphedema symptoms.
    Gynecol Oncol. 2023;170:254-258.
    PubMed     Abstract available


  38. HOLLOWAY SB, Mercadel AJ, Miller DS, Lea JS, et al
    Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma.
    Gynecol Oncol. 2023;170:248-253.
    PubMed     Abstract available


  39. GILBERT L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, et al
    Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2023;170:241-247.
    PubMed     Abstract available


  40. BOITANO TKL, Scarinci IC
    Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer.
    Gynecol Oncol. 2023;169:A1-A2.
    PubMed    


  41. BERCOW AS, Rauh-Hain JA, Melamed A, Mazina V, et al
    Association of hospital-level factors with utilization of sentinel lymph node biopsy in patients with early-stage vulvar cancer.
    Gynecol Oncol. 2023;169:47-54.
    PubMed     Abstract available


    January 2023
  42. STRAUBHAR AM, Stroup C, de Bear O, Dalton L, et al
    Provider compliance with a tailored opioid prescribing calculator in gynecologic surgery.
    Gynecol Oncol. 2023;170:229-233.
    PubMed     Abstract available


  43. DAVIDSON TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, et al
    Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:221-228.
    PubMed     Abstract available


  44. ZHANG Y, Yang R, Xu C, Zhang Y, et al
    Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
    Gynecol Oncol. 2023;170:210-220.
    PubMed     Abstract available


  45. HAIGHT PJ, Barrington DA, Graves SM, Piver RN, et al
    Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population.
    Gynecol Oncol. 2023;170:203-209.
    PubMed     Abstract available


  46. JAMIESON A, Singh N, Huvila J, Gilks CB, et al
    The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
    Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
    PubMed    


  47. CIBULA D, Akilli H, Jarkovsky J, van Lonkhuijzen L, et al
    Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
    Gynecol Oncol. 2023;170:195-202.
    PubMed     Abstract available


  48. FERRON G, De Rauglaudre G, Becourt S, Delanoy N, et al
    Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
    Gynecol Oncol. 2023;170:186-194.
    PubMed     Abstract available


  49. BRAGA A, Andrade T, do Carmo Borges de Souza M, Campos V, et al
    Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and lit
    Gynecol Oncol. 2023;170:179-185.
    PubMed     Abstract available


  50. HAN C, McNamara B, Bellone S, Harold J, et al
    The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
    Gynecol Oncol. 2023;170:172-178.
    PubMed     Abstract available


  51. MOUFARRIJ S, Sassine D, Basaran D, Jewell EL, et al
    Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
    Gynecol Oncol. 2023;170:167-171.
    PubMed     Abstract available


  52. MITRIC C, Salman L, Abrahamyan L, Kim SR, et al
    Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;170:133-142.
    PubMed     Abstract available


  53. SUVAAL I, Kirchheiner K, Nout RA, Sturdza AE, et al
    Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy.
    Gynecol Oncol. 2023;170:123-132.
    PubMed     Abstract available


  54. JAREEMIT N, Therasakvichya S, Freitas F, Paiva G, et al
    EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
    Gynecol Oncol. 2023;170:114-122.
    PubMed     Abstract available


  55. NAVARRO AS, Gomez CM, Angeles MA, Fuzier R, et al
    Open abdominal vacuum pack technique for the management of severe abdominal complications after cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2023;170:108-113.
    PubMed     Abstract available


  56. JOHNSON AM, Teoh D, Jewett P, Darst BF, et al
    Genetic variants associated with post-traumatic stress symptoms in patients with gynecologic cancer.
    Gynecol Oncol. 2023;170:102-107.
    PubMed     Abstract available


  57. SMITS A, Ten Eikelder M, Dhanis J, Moore W, et al
    Finding the sentinel lymph node in early cervical cancer: When is unusual not uncommon?
    Gynecol Oncol. 2023;170:84-92.
    PubMed     Abstract available


  58. ORELLANA TJ, Garrett AA, Soong TR, Rives T, et al
    The role of adjuvant treatment for early-stage uterine clear cell carcinomas.
    Gynecol Oncol. 2023;170:77-83.
    PubMed     Abstract available


  59. SHIRLEY J, Lambert P, Nachtigal MW, Altman AD, et al
    A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer.
    Gynecol Oncol. 2023;170:54-58.
    PubMed     Abstract available


  60. TOGAMI S, Tanimoto A, Yanazume S, Tokunaga H, et al
    Evaluation of the one-step nucleic acid amplification assay for detecting lymph node metastasis in patients with cervical and endometrial cancer: A multicenter prospective study.
    Gynecol Oncol. 2023;170:70-76.
    PubMed     Abstract available


  61. LU L, Liu T, Wang S, Li J, et al
    Joint detection of multiple HPV-testing technologies and evaluation of clinicopathological characteristics discriminate between HPV-independent and low-copy HPV-associated cervical squamous cell carcinoma (CSCC) -an analysis of 3869 cases.
    Gynecol Oncol. 2023;170:59-69.
    PubMed     Abstract available


  62. KAHN RM, McMinn E, Yeoshoua E, Boerner T, et al
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
    Gynecol Oncol. 2023;170:46-53.
    PubMed     Abstract available


  63. MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
    Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Gynecol Oncol. 2023;170:38-45.
    PubMed     Abstract available


  64. WANG DF, Shi XW, Zhang C, Zhang J, et al
    Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    Gynecol Oncol. 2023;170:25-31.
    PubMed     Abstract available


  65. KIM JH, Chun SY, Lee DE, Woo YH, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
    Gynecol Oncol. 2023;170:19-24.
    PubMed     Abstract available


  66. THOMSON CA, Crane TE, Miller A, Gold MA, et al
    Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2023;170:11-18.
    PubMed     Abstract available


  67. PETERS PN, Rossi EC
    Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?
    Gynecol Oncol. 2023;168:A2-A3.
    PubMed    


    December 2022
  68. ASIF H, Foley G, Simon M, Roque D, et al
    Analysis of endometrial carcinoma TCGA reveals differences in DNA methylation in tumors from Black and White women.
    Gynecol Oncol. 2022;170:1-10.
    PubMed     Abstract available


  69. DINIZ TP, Menezes JN, Goncalves BT, Faloppa CC, et al
    Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?
    Gynecol Oncol. 2022;169:131-136.
    PubMed     Abstract available


  70. EHMANN S, Shay K, Zhou Q, Iasonos A, et al
    Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2022;169:118-124.
    PubMed     Abstract available


  71. CASTELLANO T, Moore K, Ting J, Washington C, et al
    Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.
    Gynecol Oncol. 2022;169:113-117.
    PubMed     Abstract available


  72. LI X, Jiang Z, Lu J, Chen X, et al
    Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer.
    Gynecol Oncol. 2022;169:106-112.
    PubMed     Abstract available


  73. ARMSTRONG DK
    AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
    Gynecol Oncol. 2022 Dec 15:S0090-8258(22)01961.
    PubMed    


  74. MANAVELLA DD, McNamara B, Harold J, Bellone S, et al
    Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
    Gynecol Oncol. 2022;169:98-105.
    PubMed     Abstract available


  75. LIN MY, Mileshkin L, McNally O, Kondalsamy-Chennakesavan S, et al
    Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection.
    Gynecol Oncol. 2022;169:91-97.
    PubMed     Abstract available


  76. KAHN R, Filippova O, Gordhandas S, An A, et al
    Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
    Gynecol Oncol. 2022;169:85-90.
    PubMed     Abstract available


  77. COLOMBA E, Alexandre J, Le Teuff G, Genestie C, et al
    Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
    Gynecol Oncol. 2022;169:78-84.
    PubMed     Abstract available


  78. BOONE RM, Praiss AM, Huang Y, Melamed A, et al
    Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials.
    Gynecol Oncol. 2022;169:70-77.
    PubMed     Abstract available


  79. RUBINSTEIN MM, Doria ER, Konner J, Lichtman S, et al
    Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
    Gynecol Oncol. 2022;169:64-69.
    PubMed     Abstract available


  80. WOOD N, Morton M, Shah SN, Yao M, et al
    Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2022;169:55-63.
    PubMed     Abstract available


  81. REID HW, Selvan B, Montes de Oca MK, Falkovic M, et al
    "You start feeling comfortable, you just start sharing:" A qualitative study of patient distress screening in Black and White patients with endometrial cancer.
    Gynecol Oncol. 2022;168:166-175.
    PubMed     Abstract available


  82. NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
    Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2022;169:41-46.
    PubMed     Abstract available


  83. PARKER VL, Cushen BF, Hills A, Kandiah K, et al
    Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2022;169:34-40.
    PubMed     Abstract available


  84. DI DIO C, Bogani G, Di Donato V, Cuccu I, et al
    The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Gynecol Oncol. 2022;169:27-33.
    PubMed     Abstract available


  85. DU J, Cheng Y, Hu D, Xing Y, et al
    A nomogram-based overall survival stratification to identify uterine sarcoma patients without distant metastases who may benefit from adjuvant radiotherapy.
    Gynecol Oncol. 2022;169:17-26.
    PubMed     Abstract available


  86. KIM SR, Ene GEV, Simpson A, Gesink D, et al
    Acceptability of bariatric surgery in people with endometrial cancer and atypical hyperplasia: A qualitative study.
    Gynecol Oncol. 2022;169:12-16.
    PubMed     Abstract available


  87. MATULONIS UA
    The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data.
    Gynecol Oncol. 2022;167:401-403.
    PubMed    


  88. EHMANN S, Sassine D, Straubhar AM, Praiss AM, et al
    Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
    Gynecol Oncol. 2022;167:458-466.
    PubMed     Abstract available


    November 2022
  89. VIEIRA-SERNA S, Viveros-Carreno D, Rodriguez J, Grillo-Ardila CF, et al
    Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022;169:4-11.
    PubMed     Abstract available


  90. CRUM CP, Yoon JY, Feltmate CM
    Clinical commentary extra-uterine high-grade serous carcinoma: Two pathways, two preventions?
    Gynecol Oncol. 2022;169:1-3.
    PubMed    


  91. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
    Gynecol Oncol. 2022 Nov 28:S0090-8258(22)01924.
    PubMed    


  92. HAROLD J, Bellone S, Manavella DD, Mutlu L, et al
    Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
    Gynecol Oncol. 2022;168:157-165.
    PubMed     Abstract available


  93. DOSTALEK L, Benesova K, Klat J, Kim SH, et al
    Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project.
    Gynecol Oncol. 2022;168:151-156.
    PubMed     Abstract available


  94. SALINARO JR, Zanolli N, Truong T, Havrilesky LJ, et al
    Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative.
    Gynecol Oncol. 2022;168:144-150.
    PubMed     Abstract available


  95. SHU T, Zhou Z, Bai J, Xiao X, et al
    Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2022;168:135-143.
    PubMed     Abstract available


  96. AKESSON A, Adok C, Dahm-Kahler P
    Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study.
    Gynecol Oncol. 2022;168:127-134.
    PubMed     Abstract available


  97. KARIA PS, Huang Y, Tehranifar P, Wright JD, et al
    Racial and ethnic differences in type II endometrial cancer mortality outcomes: The contribution of sociodemographic, clinicopathologic, and treatment factors.
    Gynecol Oncol. 2022;168:119-126.
    PubMed     Abstract available


  98. MYSONA D, Dorr K, Ward A, Shaver E, et al
    Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
    Gynecol Oncol. 2022;168:114-118.
    PubMed     Abstract available


  99. WESTIN SN, Fu S, Tsimberidou A, Piha-Paul S, et al
    Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Gynecol Oncol. 2022;168:76-82.
    PubMed     Abstract available


  100. MATANES E, Amajoud Z, Kogan L, Mitric C, et al
    Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?
    Gynecol Oncol. 2022;168:107-113.
    PubMed     Abstract available


  101. MOUKARZEL LA, Nguyen N, Zhou Q, Iasonos A, et al
    Association of bowel preparation with surgical-site infection in gynecologic oncology surgery: Post-hoc analysis of a randomized controlled trial.
    Gynecol Oncol. 2022;168:100-106.
    PubMed     Abstract available


  102. ZHAO L, Qin Y, Ma D, Liu H, et al
    Corrigendum to "Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study" [Gynecologic Oncology Volume 167, Issue 3, Oct 2022 Pages 37-41].
    Gynecol Oncol. 2022 Nov 18:S0090-8258(22)01925.
    PubMed    


  103. MARK J, Fisher DT, Kim M, Emmons T, et al
    Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
    Gynecol Oncol. 2022;168:92-99.
    PubMed     Abstract available


  104. YANAIHARA N, Yoshino Y, Noguchi D, Tabata J, et al
    Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    Gynecol Oncol. 2022;168:83-91.
    PubMed     Abstract available


  105. PHUNG MT, Webb PM, DeFazio A, Fereday S, et al
    Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
    Gynecol Oncol. 2022;168:68-75.
    PubMed     Abstract available


  106. YOU B, Bolze PA, Lotz JP, Massardier J, et al
    Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
    Gynecol Oncol. 2022;168:62-67.
    PubMed     Abstract available


  107. BRUEGL AS, Emerson J, Tirumala K
    Persistent disparities of cervical cancer among American Indians/Alaska natives: Are we maximizing prevention tools?
    Gynecol Oncol. 2022;168:56-61.
    PubMed     Abstract available


  108. WALSH CS, Hacker KE, Secord AA, DeLair DF, et al
    Molecular testing for endometrial cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2022;168:48-55.
    PubMed     Abstract available


  109. KNAUSS T, Hansen BT, Pedersen K, Aasbo G, et al
    The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial.
    Gynecol Oncol. 2022;168:39-47.
    PubMed     Abstract available


  110. KA K, Laville A, Rassy E, Ayachi RE, et al
    Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
    Gynecol Oncol. 2022;168:32-38.
    PubMed     Abstract available


  111. MEAGHER NS, Hamilton P, Milne K, Thornton S, et al
    Profiling the immune landscape in mucinous ovarian carcinoma.
    Gynecol Oncol. 2022;168:23-31.
    PubMed     Abstract available


  112. PIAO H, Wu M, Qin S, Tang Z, et al
    Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2022;168:17-22.
    PubMed     Abstract available


  113. KIM H, Kim HJ, Ahn HS
    Does endometriosis increase the risks of endometrial hyperplasia and endometrial cancer?
    Gynecol Oncol. 2022 Nov 7. pii: S0090-8258(22)00425.
    PubMed     Abstract available


  114. KELKAR SS, Prabhu VS, Corman S, Odak S, et al
    Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01893.
    PubMed     Abstract available


  115. PETERS PN, Moyett JM, Davidson BA, Cantrell S, et al
    Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
    Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01890.
    PubMed     Abstract available


  116. MUELLER JJ, Rios-Doria E, Park KJ, Broach VA, et al
    Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
    Gynecol Oncol. 2022;168:1-7.
    PubMed     Abstract available


  117. ACKROYD SA, Arguello D, Ramos P, Mahdi H, et al
    Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
    Gynecol Oncol. 2022 Nov 1. pii: S0090-8258(22)01897.
    PubMed     Abstract available


    October 2022
  118. RUBINSTEIN M, Shen S, Monk BJ, Tan DSP, et al
    Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2022 Oct 21. pii: S0090-8258(22)01889.
    PubMed     Abstract available


  119. O'MALLEY DM, Oza AM, Lorusso D, Aghajanian C, et al
    Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)00575.
    PubMed     Abstract available


  120. KIM SI, Kim JH, Lee S, Cho H, et al
    Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01887.
    PubMed     Abstract available


  121. JORGE S
    Health Equity in Gynecologic Oncology: Focus on Limited English Proficiency.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01861.
    PubMed    


  122. CHENG A, Rao Q, Liu Y, Huang C, et al
    Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01888.
    PubMed     Abstract available


  123. HINCHCLIFF E, Rumpf J, Ratan R, Fleming ND, et al
    Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma.
    Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01852.
    PubMed     Abstract available


  124. EBATA T, Yamashita S, Takeshima H, Yoshida H, et al
    DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2022 Oct 14. pii: S0090-8258(22)01881.
    PubMed     Abstract available


  125. FARLEY JH, Brady WE, O'Malley D, Fujiwara K, et al
    A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01862.
    PubMed     Abstract available


  126. CHAN JK, Tian C, Kesterson JP, Richardson MT, et al
    The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01856.
    PubMed     Abstract available


  127. SMITH AJB, Mulugeta-Gordon L, Pena D, Kanter GP, et al
    Prior authorization in gynecologic oncology: An analysis of clinical impact.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01858.
    PubMed     Abstract available


  128. GARZON S, Grassi T, Mariani A, Kollikonda S, et al
    Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01860.
    PubMed     Abstract available


  129. KURNIT KC, Nobre SP, Fellman BM, Iglesias DA, et al
    Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
    Gynecol Oncol. 2022 Oct 12. pii: S0090-8258(22)01853.
    PubMed     Abstract available


  130. ELNAGGAR A, Robins D, Baca Y, Arguello D, et al
    Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
    Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01850.
    PubMed     Abstract available


  131. MITRA D, Farr M, Nagarajan P, Ho J, et al
    Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
    Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01854.
    PubMed     Abstract available


  132. LORUSSO D, Pignata S, Tamberi S, Mangili G, et al
    Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01851.
    PubMed     Abstract available


  133. POWELL CB, Laurent C, Garcia C, Hoodfar E, et al
    Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01857.
    PubMed     Abstract available


  134. VON KARTASCHEW AE, Dahm-Kahler P, Rodriguez-Wallberg KA, Holmberg E, et al
    Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study.
    Gynecol Oncol. 2022 Oct 7. pii: S0090-8258(22)01855.
    PubMed     Abstract available


  135. CAO Y, Viswanathan A
    When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?
    Gynecol Oncol. 2022;167:1-2.
    PubMed    


  136. VAN DER KOLK WL, Van der Zee AGJ, Slomovitz BM, Baldwin PJW, et al
    Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.
    Gynecol Oncol. 2022;167:3-10.
    PubMed     Abstract available


  137. PERKINS R, Jeronimo J, Hammer A, Novetsky A, et al
    Comparison of accuracy and reproducibility of colposcopic impression based on a single image versus a two-minute time series of colposcopic images.
    Gynecol Oncol. 2022;167:89-95.
    PubMed     Abstract available


  138. CHEN H, Xiong W, Dong X, Liu Y, et al
    Infection status and survival impact of high-risk human papillomavirus in cervical adenocarcinomas: A systematic review and meta-analysis.
    Gynecol Oncol. 2022;167:129-136.
    PubMed     Abstract available


    September 2022
  139. HELPMAN L, Pond GR, Elit L, Anderson LN, et al
    Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study.
    Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01829.
    PubMed     Abstract available


  140. KONSTANTINOPOULOS PA, Lee JM, Gao B, Miller R, et al
    A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
    Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01839.
    PubMed     Abstract available


  141. HOLM J, Gerke O, Vilstrup MH, Spasojevic D, et al
    Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification.
    Gynecol Oncol. 2022 Sep 28. pii: S0090-8258(22)01841.
    PubMed     Abstract available


  142. BUCKLEY E, Mullen MM, Nizamuddin RA, Stein JH, et al
    High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer.
    Gynecol Oncol. 2022 Sep 27. pii: S0090-8258(22)01824.
    PubMed     Abstract available


  143. MAH SJ, Seow H, Schnarr K, Reade CJ, et al
    Trends in quality indicators of end-of-life care for women with gynecologic malignancies in Ontario, Canada.
    Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01822.
    PubMed     Abstract available


  144. EGAN D, Moran B, Wilkinson M, Pinyol M, et al
    CRABP2 - A novel biomarker for high-risk endometrial cancer.
    Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01840.
    PubMed     Abstract available


  145. RIEDINGER CJ, Patterson JM, Backes FJ, O'Malley D, et al
    The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01828.
    PubMed     Abstract available


  146. YFAT K, Mariam K, Mario B, Hal H, et al
    Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)00574.
    PubMed     Abstract available


  147. GLASER GE, Lara OD, Pothuri B, Grimaldi CG, et al
    Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01837.
    PubMed     Abstract available


  148. WICKLINE M, Wolpin S, Cho S, Tomashek H, et al
    Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01825.
    PubMed     Abstract available


  149. BERGER AA, Kawaler EA, Dao F, Misirlioglu S, et al
    The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01827.
    PubMed     Abstract available


  150. RONSINI C, Kohler C, de Franciscis P, La Verde M, et al
    Laparo-assisted vaginal radical hysterectomy as a safe option for minimal invasive surgery in early stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)00580.
    PubMed     Abstract available


  151. LEE YW, Morgan JR, Fiascone S, Perkins RB, et al
    Underscreenng, overscreening, and guideline-adherent cervical cancer screening in a national cohort.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01826.
    PubMed     Abstract available


  152. GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al
    Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
    Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591.
    PubMed     Abstract available


  153. HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
    Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
    PubMed     Abstract available


  154. CROCE S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, et al
    Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00515.
    PubMed     Abstract available


  155. YU S, Yang R, Xu T, Li X, et al
    Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
    PubMed     Abstract available


  156. RUSH SK, Lees BF, Huang DS, Peterson MF, et al
    Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577.
    PubMed     Abstract available


  157. KLC TR, Wu S, Wilhite AM, Jones NL, et al
    HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00592.
    PubMed     Abstract available


  158. VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al
    The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570.
    PubMed     Abstract available


  159. LI N, Zhu X, Nian W, Li Y, et al
    Blood-based DNA methylation profiling for the detection of ovarian cancer.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
    PubMed     Abstract available


  160. PUJADE-LAURAINE E, Tan DSP, Leary A, Mirza MR, et al
    Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00552.
    PubMed     Abstract available


  161. VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
    Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
    Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
    PubMed     Abstract available


  162. MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
    HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
    Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
    PubMed     Abstract available


  163. DAVIDSON BA, Turner TB, Kim KH, Cass I, et al
    SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology.
    Gynecol Oncol. 2022 Sep 2. pii: S0090-8258(22)00572.
    PubMed     Abstract available


  164. LAGO V, Segarra-Vidal B, Cappucio S, Angeles MA, et al
    OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
    Gynecol Oncol. 2022 Sep 1. pii: S0090-8258(22)00542.
    PubMed     Abstract available


  165. VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
    Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
    Gynecol Oncol. 2022;166:530-537.
    PubMed     Abstract available


  166. MATTSON J, Emerson J, Underwood A, Sun G, et al
    Superficial versus deep inguinal nodal dissection for vulvar cancer staging.
    Gynecol Oncol. 2022;166:465-470.
    PubMed     Abstract available


  167. KUMAR A
    Answering the call: Are we ready for action on frailty in gynecologic oncology?
    Gynecol Oncol. 2022;166:377-378.
    PubMed    


    August 2022
  168. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
    Gynecol Oncol. 2022 Aug 31. pii: S0090-8258(22)00573.
    PubMed     Abstract available


  169. BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al
    Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551.
    PubMed     Abstract available


  170. MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al
    Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovaria
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544.
    PubMed     Abstract available


  171. BOKKERS K, Frederix GWJ, Velthuizen ME, van der Aa M, et al
    Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    Gynecol Oncol. 2022 Aug 25. pii: S0090-8258(22)00550.
    PubMed     Abstract available


  172. ANDERSON C, Olshan AF, Bae-Jump VL, Brewster WR, et al
    Cardiovascular disease diagnoses among older women with endometrial cancer.
    Gynecol Oncol. 2022 Aug 22. pii: S0090-8258(22)00553.
    PubMed     Abstract available


  173. LAI YL, Chang CS, Chang K, Kim HS, et al
    Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.
    Gynecol Oncol. 2022 Aug 19. pii: S0090-8258(22)00547.
    PubMed     Abstract available


  174. THOMAS QD, Boussere A, Classe JM, Pomel C, et al
    Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
    PubMed     Abstract available


  175. KIM Y, Kim SI, Kim H, Lee M, et al
    Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00541.
    PubMed     Abstract available


  176. VAHTERISTO M, Heinavaara S, Anttila A, Sarkeala T, et al
    Alternative cytology triage strategies for primary HPV screening.
    Gynecol Oncol. 2022 Aug 10. pii: S0090-8258(22)00495.
    PubMed     Abstract available


  177. DEMARI JA, Shalowitz DI
    Routine informed consent for mismatch repair testing in endometrial cancers: Review and ethical analysis.
    Gynecol Oncol. 2022 Aug 8. pii: S0090-8258(22)00540.
    PubMed     Abstract available


  178. MOSS KM, Mishra GD, Krejany EO, Hickey M, et al
    What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2022 Aug 3. pii: S0090-8258(22)00513.
    PubMed     Abstract available


  179. ZHAO L, Qin Y, Ma D, Liu H, et al
    Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00514.
    PubMed     Abstract available


  180. KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
    Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
    PubMed     Abstract available


  181. SHAPIRA-FROMMER R, Mileshkin L, Manzyuk L, Penel N, et al
    Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
    Gynecol Oncol. 2022;166:211-218.
    PubMed     Abstract available


  182. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
    Gynecol Oncol. 2022;166:370-371.
    PubMed    


  183. MARION S, Aviki E, Chino F
    Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy.
    Gynecol Oncol. 2022;166:197-199.
    PubMed    


    July 2022
  184. SIVARS L, Hellman K, Crona Guterstam Y, Holzhauser S, et al
    Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00512.
    PubMed     Abstract available


  185. HOARE JI, Hockings H, Saxena J, Silva VL, et al
    A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
    PubMed     Abstract available


  186. ALHOLM Z, He D, Ting J, Zhang YJ, et al
    Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00509.
    PubMed     Abstract available


  187. SHRESTHA P, Poudyal B, Yadollahi S, E Wright D, et al
    A systematic review on the use of artificial intelligence in gynecologic imaging - Background, state of the art, and future directions.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00496.
    PubMed     Abstract available


  188. BOGANI G, Donato VD, Scambia G, Landoni F, et al
    Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00494.
    PubMed     Abstract available


  189. LEWIS GK, Ghaith S, Craver EC, Li Z, et al
    The association of endosalpingiosis with gynecologic malignancy.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00510.
    PubMed     Abstract available


  190. BARRINGTON DA, Calo C, Baek J, Brown M, et al
    Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy.
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00482.
    PubMed     Abstract available


  191. KIM YN, Lee D, Cha J, Kang WJ, et al
    Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity?
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00487.
    PubMed     Abstract available


  192. JOLY F, Fabbro M, Berton D, Lequesne J, et al
    Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
    PubMed     Abstract available


  193. LIANG MI, Simons JL, Herbey I, Wall JA, et al
    Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
    PubMed     Abstract available



  194. The implications of the loss of abortion services from the perspective of the gynecologic cancer care team.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00491.
    PubMed    


  195. BARRINGTON DA, Meade CE, Cosgrove CM, Cohn DE, et al
    Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer.
    Gynecol Oncol. 2022 Jul 23. pii: S0090-8258(22)00486.
    PubMed     Abstract available


  196. SHALOWITZ DI, Charlton ME
    The road to geographic equity in access to gynecologic cancer care.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00490.
    PubMed    


  197. LEITAO MM JR, Zhou QC, Brandt B, Iasonos A, et al
    The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00434.
    PubMed     Abstract available


  198. LEVINE MD, Barrington DA, Hampel H, Goodfellow PJ, et al
    Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    Gynecol Oncol. 2022 Jul 20. pii: S0090-8258(22)00488.
    PubMed     Abstract available


  199. LI H, Wang S, Liu Y, Wang T, et al
    Prophylactic extended-field irradiation for locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jul 19. pii: S0090-8258(22)00481.
    PubMed     Abstract available


  200. TUCKER K, Sullivan S, Deal AM, Allman K, et al
    A prospective randomized trial of standard versus multimedia-supplemented counseling in patients undergoing endometrial cancer staging surgery.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00485.
    PubMed     Abstract available


  201. ALHILLI MM, Schold JD, Kelley J, Tang AS, et al
    Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncology.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00435.
    PubMed     Abstract available


  202. KIM SI, Kim JH, Noh JJ, Kim SH, et al
    Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
    PubMed     Abstract available


  203. CHASE DM, Marin MR, Backes F, Han S, et al
    Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
    Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
    PubMed     Abstract available


  204. BENICHOU J, Schwall C, Sastre-Garau X, Mereaux J, et al
    Impact of the new molecular classification of endometrial cancer: A French cohort study.
    Gynecol Oncol. 2022 Jul 14. pii: S0090-8258(22)00484.
    PubMed     Abstract available


  205. HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
    Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
    PubMed     Abstract available


  206. PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
    What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
    PubMed     Abstract available


  207. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00405.
    PubMed     Abstract available


  208. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    PubMed     Abstract available


  209. MCDONALD V, Wang Y, Patel A, Betcher R, et al
    Laparoscopic guided liposomal bupivacaine injection compared to transversus abdominus plane block for postoperative pain after robotic gynecologic oncology surgery.
    Gynecol Oncol. 2022 Jul 8. pii: S0090-8258(22)00406.
    PubMed     Abstract available


  210. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    PubMed     Abstract available


  211. TSENG JH, Bristow RE
    Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
    Gynecol Oncol. 2022;166:5-7.
    PubMed    


  212. HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
    Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
    Gynecol Oncol. 2022;166:50-56.
    PubMed     Abstract available


  213. MOKHTECH M, Gao SJ, Kassick M, Menderes G, et al
    Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer.
    Gynecol Oncol. 2022;166:61-68.
    PubMed     Abstract available


  214. O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Gynecol Oncol. 2022;166:36-43.
    PubMed     Abstract available


  215. NELSON G
    Social media in gynecologic oncology: A new frontier.
    Gynecol Oncol. 2022;166:3-4.
    PubMed    


  216. GEHRIG PA, Farley J
    Introducing a new series in Gynecologic Oncology: Health equity in gynecologic oncology research.
    Gynecol Oncol. 2022;166:1-2.
    PubMed    


  217. CHERSTON C, Yoh K, Huang Y, Melamed A, et al
    Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.
    Gynecol Oncol. 2022 Jul 1. pii: S0090-8258(22)00427.
    PubMed     Abstract available


    June 2022
  218. LIU K, Zhu Y, Zhou Y, Zhang Y, et al
    Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00419.
    PubMed     Abstract available


  219. MUNOZ JL, Blankenship LM, Ramsey PS, McCann GA, et al
    Importance of the gynecologic oncologist in management of cesarean hysterectomy for Placenta Accreta Spectrum (PAS).
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00429.
    PubMed     Abstract available


  220. SY F, Greuel M, Winkler V, Bussmann H, et al
    Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00416.
    PubMed     Abstract available


  221. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    PubMed     Abstract available


  222. ROGOWSKI P, Rottler M, Walter F, Saicic S, et al
    Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jun 25. pii: S0090-8258(22)00423.
    PubMed     Abstract available


  223. BACORRO W, Baldivia K, Yu KK, Mariano J, et al
    Outcomes with definitive radiotherapy among patients with locally advanced cervical cancer with relative or absolute contraindications to cisplatin: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 24. pii: S0090-8258(22)00422.
    PubMed     Abstract available


  224. HEFFERNAN K, Nikitas FS, Shukla U, Camejo HS, et al
    Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
    Gynecol Oncol. 2022 Jun 22. pii: S0090-8258(22)00415.
    PubMed     Abstract available


  225. DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
    Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
    PubMed     Abstract available


  226. RASMUSSEN CL, Thomsen LT, Baandrup L, Franzmann MB, et al
    Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00418.
    PubMed     Abstract available


  227. KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
    Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
    PubMed     Abstract available


  228. AO M, Zheng D, Wang J, Gu X, et al
    Corrigendum to "Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia" [Gynecologic Oncology, Volume 162, Issue 3, September 2021, Pages 584-589].
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00411.
    PubMed    


  229. KIM NR, Lee AJ, Yang EJ, So KA, et al
    Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
    PubMed     Abstract available


  230. BOGANI G, Di Donato V, Papadia A, Buda A, et al
    Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00407.
    PubMed     Abstract available


  231. CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
    Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
    Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
    PubMed     Abstract available


  232. JERNIGAN A, Farley J, Walsh C
    Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2022 Jun 15. pii: S0090-8258(22)00410.
    PubMed    


  233. NAKAMURA K, Shigeyasu K, Okamoto K, Matsuoka H, et al
    ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.
    Gynecol Oncol. 2022 Jun 10. pii: S0090-8258(22)00337.
    PubMed     Abstract available


  234. HEALD B, Mokhtary S, Nielsen SM, Rojahn S, et al
    Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00334.
    PubMed     Abstract available


  235. SCHIFF JP, Mintz R, Cohen AC, Huang Y, et al
    Overall survival in patients with FIGO stage IVA cervical cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00333.
    PubMed     Abstract available


  236. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
    PubMed     Abstract available


  237. LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
    Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
    PubMed     Abstract available


  238. ZHOU N, Cui Y, Zhu R, Kuang Y, et al
    Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00306.
    PubMed     Abstract available


  239. HORSBOL TA, Kjaer SK, Andersen EW, Ammitzboll G, et al
    Use of hypnotics among women diagnosed with cervical cancer - A population-based cohort study.
    Gynecol Oncol. 2022 Jun 6. pii: S0090-8258(22)00330.
    PubMed     Abstract available


  240. NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
    Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
    Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
    PubMed     Abstract available


  241. DIGGS A, Sia TY, Huang Y, Gockley A, et al
    Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Gynecol Oncol. 2022 Jun 2. pii: S0090-8258(22)00329.
    PubMed     Abstract available


  242. GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
    Gynecol Oncol. 2022;165:560-567.
    PubMed     Abstract available


  243. MARTIN AL, Sinha S, Peres LC, Hakam A, et al
    The impact of distance to closest negative margin on survival after pelvic exenteration.
    Gynecol Oncol. 2022;165:514-521.
    PubMed     Abstract available


  244. SCHNACK TH, Froeding LP, Kristensen E, Niemann I, et al
    Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study.
    Gynecol Oncol. 2022;165:420-427.
    PubMed     Abstract available


  245. HOU X, Zhai Y, Hu K, Liu CJ, et al
    Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Gynecol Oncol. 2022;165:552-559.
    PubMed     Abstract available


  246. FELIX AS, Addison D
    The intersection of gynecologic cancer, obesity, and cardiovascular disease.
    Gynecol Oncol. 2022;165:403-404.
    PubMed    


  247. NG AP, Sanaiha Y, Verma A, Lee C, et al
    Insurance-based disparities and risk of financial toxicity among patients undergoing gynecologic cancer operations.
    Gynecol Oncol. 2022 Jun 1. pii: S0090-8258(22)00328.
    PubMed     Abstract available


    May 2022
  248. YADAV G, Roque DM, Bellone S, Manavella DD, et al
    Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
    Gynecol Oncol. 2022 May 28. pii: S0090-8258(22)00332.
    PubMed     Abstract available


  249. PIEDIMONTE S, Pond GR, Plante M, Nelson G, et al
    Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.
    Gynecol Oncol. 2022 May 26. pii: S0090-8258(22)00310.
    PubMed     Abstract available


  250. GORGEU V, Borghese B, Koual M, Just PA, et al
    Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.
    Gynecol Oncol. 2022 May 25. pii: S0090-8258(22)00321.
    PubMed     Abstract available


  251. NOLIN AC, Tian C, Hamilton CA, Casablanca Y, et al
    Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.
    Gynecol Oncol. 2022 May 24. pii: S0090-8258(22)00312.
    PubMed     Abstract available


  252. BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
    End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
    PubMed     Abstract available


  253. GENNARI P, Tchaikovski S, Meszaros J, Gerken M, et al
    Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00313.
    PubMed     Abstract available


  254. MAH SJ, Anpalagan T, Marcucci M, Eiriksson L, et al
    The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology.
    Gynecol Oncol. 2022 May 20. pii: S0090-8258(22)00311.
    PubMed     Abstract available


  255. TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
    Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
    PubMed     Abstract available


  256. MARSH LA, Aviki EM, Wright JD, Chen L, et al
    Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform.
    Gynecol Oncol. 2022 May 18. pii: S0090-8258(22)00308.
    PubMed     Abstract available


  257. ZHOU S, Liu S, Tian G, Zhao L, et al
    KLK5 is associated with the radioresistance, aggression, and progression of cervical cancer.
    Gynecol Oncol. 2022 May 17. pii: S0090-8258(22)00309.
    PubMed     Abstract available


  258. WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
    Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
    PubMed     Abstract available


  259. HINCHCLIFF E, Westin SN, Herzog TJ
    State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
    PubMed    


  260. ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
    The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
    PubMed     Abstract available


  261. GUIDA F, Dioun S, Fagotti A, Melamed A, et al
    Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
    PubMed     Abstract available


  262. MCKINNISH TR, Greenwade MM, Wilkinson-Ryan I, Schwarz JK, et al
    Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
    Gynecol Oncol. 2022 May 7. pii: S0090-8258(22)00259.
    PubMed     Abstract available


  263. DEMARI JA, Boyles GP, Barrington DA, Audrey Busho BS, et al
    Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy.
    Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00261.
    PubMed     Abstract available


  264. STENZEL AE, Thomaier L, Jewett PI, Dona AC, et al
    Interactions between physical activity and type of cancer treatment received on associations with psychosocial outcomes among gynecologic cancer survivors.
    Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00260.
    PubMed     Abstract available


  265. RONSINI C, Kohler C, De Franciscis P, La Verde M, et al
    Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 2. pii: S0090-8258(22)00251.
    PubMed     Abstract available


  266. JAMIESON A, Thompson EF, Huvila J, Leung S, et al
    Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.
    Gynecol Oncol. 2022;165:376-384.
    PubMed     Abstract available


  267. MAXWELL GL, Secord AA, Powell MA
    The ProMisE of uniform care for endometrial cancer patients.
    Gynecol Oncol. 2022;165:199-200.
    PubMed    


  268. KIM SK, Ursell P, Coleman RL, Monk BJ, et al
    Mitigation and management strategies for ocular events associated with tisotumab vedotin.
    Gynecol Oncol. 2022;165:385-392.
    PubMed     Abstract available


    April 2022
  269. THOMAS RJ, Provenzano D, Goyal S, Loew M, et al
    Trends in guideline-adherent chemoradiation therapy for locally advanced cervical cancer before and after the affordable care act.
    Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00256.
    PubMed     Abstract available


  270. JACKSON CG, Moore KN, Cantrell L, Erickson BK, et al
    A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
    Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00257.
    PubMed     Abstract available


  271. WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
    Molecular profiles of endometrial cancer tumors among Black patients.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
    PubMed     Abstract available


  272. XU JY, Chen JN, Lei J, Hu M, et al
    Local treatment improves survival in patients with stage IVB cervical cancer.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00254.
    PubMed     Abstract available


  273. TANIGAWA T, Takeshima N, Ishikawa H, Nishio S, et al
    Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
    Gynecol Oncol. 2022 Apr 26. pii: S0090-8258(22)00252.
    PubMed     Abstract available


  274. KARPEL HC, Chern JY, Smith J M, Smith A J, et al
    Utility of germline multi-gene panel testing in patients with endometrial cancer.
    Gynecol Oncol. 2022 Apr 25. pii: S0090-8258(22)00216.
    PubMed     Abstract available


  275. FU Z, Taylor S, Modugno F
    Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
    PubMed     Abstract available


  276. WANG D, Jia S, Jia C, Cao D, et al
    Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
    PubMed     Abstract available


  277. MA X, Ren X, Ma F, Cai S, et al
    Volumetric apparent diffusion coefficient (ADC) histogram metrics as imaging biomarkers for pretreatment predicting response to fertility-sparing treatment in patients with endometrial cancer.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00249.
    PubMed     Abstract available


  278. BARRINGTON DA, Fox B, Meade C, Quick A, et al
    Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00248.
    PubMed     Abstract available


  279. POTHURI B, Eskander RN, Randall LM, O'Malley DM, et al
    Practice changing cervical cancer clinical trials.
    Gynecol Oncol. 2022 Apr 20. pii: S0090-8258(22)00175.
    PubMed    


  280. JOOYA ND, Ciccone MA, Brunette LL, Pham HQ, et al
    Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
    Gynecol Oncol. 2022 Apr 19. pii: S0090-8258(22)00203.
    PubMed     Abstract available


  281. LUHRS O, Bollino M, Ekdahl L, Lonnerfors C, et al
    Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy.
    Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00209.
    PubMed     Abstract available


  282. COUGHLIN SS, Datta B, Guha A, Wang X, et al
    Cardiovascular conditions and obesity among gynecologic cancer survivors: Results from the 2020 behavioral risk factor surveillance system survey.
    Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00207.
    PubMed     Abstract available


  283. BARRINGTON DA, Riedinger C, Haight PJ, Tubbs C, et al
    Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2022 Apr 11. pii: S0090-8258(22)00213.
    PubMed     Abstract available


  284. LOF P, Retel VP, Algera MD, van Gent MDJM, et al
    Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
    Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
    PubMed     Abstract available


  285. SAPIENZA LG, Thomas JJ, Showalter TN, Echeverria AE, et al
    Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal.
    Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00208.
    PubMed     Abstract available


  286. CHAMBERS LM, Chalif J, Vargas R
    Analysis of patient experiences with gestational trophoblastic neoplasia reported on Instagram social media.
    Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00211.
    PubMed     Abstract available


  287. SON J, George GC, Nardo M, Krause KJ, et al
    Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00195.
    PubMed     Abstract available


  288. GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
    Germline BRCA variants, lifestyle and ovarian cancer survival.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
    PubMed     Abstract available


  289. SAND FL, Frederiksen K, Kjaer SK
    Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00197.
    PubMed     Abstract available


  290. NORPPA N, Staff S, Helminen M, Auranen A, et al
    Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
    PubMed     Abstract available


  291. BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
    The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
    PubMed     Abstract available


  292. SALVO G, Jhingran A, Ramalingam P, Legarreta AF, et al
    Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study.
    Gynecol Oncol. 2022 Apr 5. pii: S0090-8258(22)00204.
    PubMed     Abstract available


  293. HENNO S, Jeanne C, Rouge TM, Genestie C, et al
    Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
    Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
    PubMed     Abstract available


  294. POLTERAUER S, Reich O, Widschwendter A, Hadjari L, et al
    Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.
    Gynecol Oncol. 2022;165:23-29.
    PubMed     Abstract available


  295. PARPEX G, Bucau M, Estevez JP, Raimond E, et al
    Impact of vulvar reconstruction on the accuracy of a nomogram for predicting local recurrence after surgery for vulvar cancer.
    Gynecol Oncol. 2022;165:143-148.
    PubMed     Abstract available


  296. RAMOS MM, Maesta I, de Araujo Costa RA, Mazeto GMFS, et al
    Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism.
    Gynecol Oncol. 2022;165:137-142.
    PubMed     Abstract available


  297. LIAO X, Xia X, Su W, Yan H, et al
    Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
    Gynecol Oncol. 2022;165:105-113.
    PubMed     Abstract available


  298. YAZDANFARD NW, Mikkelsen LH, Behrendt N, Fuglsang K, et al
    Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival.
    Gynecol Oncol. 2022;165:53-59.
    PubMed     Abstract available


  299. VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
    Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
    Gynecol Oncol. 2022;165:114-120.
    PubMed     Abstract available


  300. KASHOFER K, Regauer S, Reich O, Petru E, et al
    Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
    Gynecol Oncol. 2022;165:121-128.
    PubMed     Abstract available


    March 2022
  301. SCHIFF JP, Mahmood M, Huang Y, Powell MA, et al
    The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00199.
    PubMed     Abstract available


  302. MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
    Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
    PubMed     Abstract available


  303. SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
    TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
    PubMed     Abstract available


  304. LIM H, In Shim J, Park SJ, Noh J, et al
    Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
    Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
    PubMed     Abstract available


  305. MOHAMUD A, Hogdall C, Schnack T
    Prognostic value of the 2018 FIGO staging system for cervical cancer.
    Gynecol Oncol. 2022 Mar 25. pii: S0090-8258(22)00127.
    PubMed     Abstract available


  306. PERRONE E, De Felice F, Capasso I, Distefano E, et al
    The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.
    Gynecol Oncol. 2022 Mar 24. pii: S0090-8258(22)00180.
    PubMed     Abstract available


  307. ZHANG L, Gu W, Zhang L, Miao R, et al
    The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial.
    Gynecol Oncol. 2022 Mar 23. pii: S0090-8258(22)00181.
    PubMed     Abstract available


  308. STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
    Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
    Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
    PubMed     Abstract available


  309. DAIX M, Martinez Gomez C, Angeles MA, Tock S, et al
    Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery.
    Gynecol Oncol. 2022 Mar 21. pii: S0090-8258(22)00174.
    PubMed     Abstract available


  310. VARGIU V, Rosati A, Capozzi VA, Sozzi G, et al
    Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study.
    Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00173.
    PubMed     Abstract available


  311. ARGENTA PA, Mattson J, Rivard CL, Luther E, et al
    Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer.
    Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00178.
    PubMed     Abstract available


  312. KULKARNI A, Sun G, Manuppelli S, Mendez H, et al
    Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers.
    Gynecol Oncol. 2022 Mar 17. pii: S0090-8258(22)00179.
    PubMed     Abstract available


  313. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
    PubMed     Abstract available


  314. HACK AP, Zweemer RP, Jonges TN, van der Leij F, et al
    Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study.
    Gynecol Oncol. 2022 Mar 14. pii: S0090-8258(22)00177.
    PubMed     Abstract available


  315. MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
    PubMed     Abstract available


  316. POST CCB, Westermann AM, Boere IA, Witteveen PO, et al
    Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
    Gynecol Oncol. 2022 Mar 11. pii: S0090-8258(22)00145.
    PubMed     Abstract available


  317. SIEGENTHALER F, Lindemann K, Epstein E, Rau TT, et al
    Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00143.
    PubMed     Abstract available


  318. HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
    Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
    PubMed     Abstract available


  319. KIM J, Noh JJ, Lee TK, Kim SI, et al
    Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00140.
    PubMed     Abstract available


  320. MATSUO K, Klar M, Khetan VU, Vallejo A, et al
    Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00144.
    PubMed     Abstract available


  321. CHALIF J, Yao M, Gruner M, Kuznicki M, et al
    Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
    PubMed     Abstract available


  322. SCHNARR KL, Seow H, Pond GR, Helpman L, et al
    The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
    Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
    PubMed     Abstract available


  323. LEITAO MM JR
    The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching.
    Gynecol Oncol. 2022;164:461-462.
    PubMed    


  324. JAMIESON A, Huvila J, Thompson EF, Leung S, et al
    Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
    Gynecol Oncol. 2022 Mar 1. pii: S0090-8258(22)00085.
    PubMed     Abstract available


  325. BRUNETTE LL, Khetan VU, Deshpande RR, Nusbaum DJ, et al
    Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States.
    Gynecol Oncol. 2022;164:651-657.
    PubMed     Abstract available


  326. SCHLEISS-ANDREASSEN JL, Kristensen E, Froding LP, Staehr E, et al
    Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma.
    Gynecol Oncol. 2022;164:543-549.
    PubMed     Abstract available


    February 2022
  327. GOINS EC, Weber JM, Truong T, Moss HA, et al
    Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
    PubMed     Abstract available


  328. PH M, Maulard A, Scherier S, Sanson C, et al
    Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00051.
    PubMed     Abstract available


  329. MATSUO K, Khetan VU, Brunette LL, Jooya ND, et al
    Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00125.
    PubMed     Abstract available


  330. ZAMMARRELLI WA 3RD, Greenman M, Rios-Doria E, Miller K, et al
    Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00122.
    PubMed     Abstract available


  331. FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
    Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
    PubMed     Abstract available


  332. MATSUO K, Chen L, Guo XM, Roman LD, et al
    Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
    Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
    PubMed     Abstract available


  333. KOBAYASHI E, Nakatani E, Tanaka T, Yosuke K, et al
    Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081.
    Gynecol Oncol. 2022 Feb 24. pii: S0090-8258(22)00089.
    PubMed     Abstract available


  334. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
    PubMed    


  335. BAETEN IGT, Hoogendam JP, Jonges GN, Jurgenliemk-Schulz IM, et al
    Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer.
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00121.
    PubMed     Abstract available


  336. ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
    Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
    PubMed     Abstract available


  337. KIM YN, Kim JC, Chung YS, Park J, et al
    Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
    PubMed     Abstract available


  338. ANDERSON EM, Luu M, Lu DJ, Chung EM, et al
    Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00024.
    PubMed     Abstract available


  339. LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
    Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
    PubMed     Abstract available


  340. HUANG Y, Hou JY, Melamed A, St Clair CM, et al
    Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer.
    Gynecol Oncol. 2022 Feb 16. pii: S0090-8258(22)00088.
    PubMed     Abstract available


  341. VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
    Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
    PubMed     Abstract available


  342. DHOLAKIA J, Liang MI, Aviki EM
    Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies.
    Gynecol Oncol. 2022 Feb 12. pii: S0090-8258(22)00087.
    PubMed    


  343. PARK J, Kim SI, Jeong SY, Kim Y, et al
    Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
    PubMed     Abstract available


  344. YAHATA H, Kodama K, Okugawa K, Hachisuga K, et al
    Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer.
    Gynecol Oncol. 2022 Feb 9. pii: S0090-8258(22)00070.
    PubMed     Abstract available


  345. KRAUS EJ, Nicosia B, Shalowitz DI
    A qualitative study of patients' attitudes towards telemedicine for gynecologic cancer care.
    Gynecol Oncol. 2022 Feb 8. pii: S0090-8258(22)00074.
    PubMed     Abstract available


  346. WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
    Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
    PubMed     Abstract available


  347. LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
    Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
    Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
    PubMed     Abstract available


  348. JOLY F, Fabbro M, Follana P, Lequesne J, et al
    A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
    Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
    PubMed     Abstract available


  349. SWIFT BE, Tigert M, Nica A, Covens A, et al
    The accuracy of intraoperative frozen section examination of sentinel lymph nodes in squamous cell cancer of the vulva.
    Gynecol Oncol. 2022;164:393-397.
    PubMed     Abstract available


  350. SHIN DW, Bae J, Ha J, Lee WM, et al
    Trends in incidence and survival of patients with vulvar cancer in an Asian country: Analysis of the Korean Central Cancer Registry 1999-2018.
    Gynecol Oncol. 2022;164:386-392.
    PubMed     Abstract available


    January 2022
  351. TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
    Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
    PubMed     Abstract available


  352. LICHTER KE, Levinson K, Hammer A, Lippitt MH, et al
    Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00025.
    PubMed     Abstract available


  353. RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
    The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
    PubMed     Abstract available


  354. WU X, Keller EJ, Rabei R, Rockwell H, et al
    Cost-effectiveness of tunneled peritoneal catheters versus repeat paracenteses for recurrent ascites in gynecologic malignancies.
    Gynecol Oncol. 2022 Jan 24. pii: S0090-8258(22)00019.
    PubMed     Abstract available


  355. RAFFONE A, Travaglino A, Raimondo D, Neola D, et al
    Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00020.
    PubMed     Abstract available


  356. WATSON CH, Monuszko K, Freeman S, Kurtovic K, et al
    Reducing non-surgical readmissions on a gynecologic oncology service.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00005.
    PubMed     Abstract available


  357. LEON-CASTILLO A, Horeweg N, Peters EEM, Rutten T, et al
    Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00007.
    PubMed     Abstract available


  358. COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
    Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
    PubMed     Abstract available


  359. XIA YY, Gronwald J, Karlan B, Lubinski J, et al
    Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
    PubMed     Abstract available


  360. BOGANI G, Ray-Coquard I, Concin N, Ngoi NYL, et al
    Clear cell carcinoma of the endometrium.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00021.
    PubMed     Abstract available


  361. SLOMOVITZ BM, Filiaci VL, Walker JL, Taub MC, et al
    A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01699.
    PubMed     Abstract available


  362. BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
    Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
    PubMed     Abstract available


  363. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
    PubMed     Abstract available


  364. ZHANG J, Yu S, Li Q, Wang Q, et al
    Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
    Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
    PubMed     Abstract available


  365. FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
    Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
    PubMed     Abstract available


  366. BEINSE G, Le Frere Belda MA, Just PA, Bekmezian N, et al
    Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00006.
    PubMed     Abstract available


  367. YAN L, Liu Y, Zhang J, Chen X, et al
    In vivo and in vitro study of the potential hazards of surgical smoke during cervical cancer treatment with an ultrasonic scalpel.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00008.
    PubMed     Abstract available


  368. ALTIN D, Taskin S, Ortac F, Tokgozoglu N, et al
    Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer: A Turkish gynecologic oncology group study (TRSGO-SLN-006).
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00003.
    PubMed     Abstract available


  369. MUSA FB, Brouwer E, Ting J, Schwartz NRM, et al
    Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
    Gynecol Oncol. 2022 Jan 11. pii: S0090-8258(21)01696.
    PubMed     Abstract available


  370. REID HW, Broadwater G, Montes de Oca MK, Selvan B, et al
    Distress screening in endometrial cancer leads to disparity in referral to support services.
    Gynecol Oncol. 2022 Jan 8. pii: S0090-8258(22)00001.
    PubMed     Abstract available


  371. TEMKIN SM, Chapman-Davis E, Nair N, Cohn DE, et al
    Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review.
    Gynecol Oncol. 2022 Jan 6. pii: S0090-8258(21)01700.
    PubMed     Abstract available


  372. AMPOFO AG, Boyes AW, Khumalo PG, Mackenzie L, et al
    Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01680.
    PubMed     Abstract available


  373. WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
    Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
    PubMed     Abstract available


  374. LIN DI, Fine A, Danziger NA, Huang RSP, et al
    Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
    PubMed     Abstract available


  375. WANG J, Dong J, Zhou Y, Wang K, et al
    Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
    Gynecol Oncol. 2022 Jan 4. pii: S0090-8258(21)01701.
    PubMed     Abstract available


  376. SHALOWITZ DI, DeMari JA
    Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
    Gynecol Oncol. 2022;164:1-2.
    PubMed    


  377. WOELBER L, Prieske K, Eulenburg CZ, Corradini S, et al
    Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2022;164:68-75.
    PubMed     Abstract available


  378. BORCINOVA M, Ragosch V, Jarkovsky J, Bajsova S, et al
    Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre study.
    Gynecol Oncol. 2022;164:76-84.
    PubMed     Abstract available


    December 2021
  379. EKDAHL L, Paraghamian S, Eoh KJ, Thumuluru KM, et al
    Long term oncologic and reproductive outcomes after robot-assisted radical trachelectomy for early-stage cervical cancer. An international multicenter study.
    Gynecol Oncol. 2021 Dec 31. pii: S0090-8258(21)01697.
    PubMed     Abstract available


  380. CORRIGAN KL, Yoder A, De B, Lin L, et al
    Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
    Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
    PubMed     Abstract available


  381. SPONHOLTZ SE, Ezendam NPM, de Rooij BH, Parner E, et al
    SENTIREC - The sentinel node mapping in women with cervical cancer study - Patient-reported early lymphedema and its impact on quality of life.
    Gynecol Oncol. 2021 Dec 29. pii: S0090-8258(21)01692.
    PubMed     Abstract available


  382. KIM SI, Choi BR, Kim HS, Chung HH, et al
    Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01691.
    PubMed     Abstract available


  383. LIGHTFOOT MDS, Felix AS, Bishop EE, Henderson AP, et al
    Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01636.
    PubMed     Abstract available


  384. THELISSEN AAB, Jurgenliemk-Schulz IM, van der Leij F, Peters M, et al
    Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01694.
    PubMed     Abstract available


  385. BEESLEY VL, Ross TL, King MT, Campbell R, et al
    Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
    PubMed     Abstract available


  386. REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
    Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
    PubMed     Abstract available


  387. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    Post-recurrence survival in patients with cervical cancer.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01675.
    PubMed     Abstract available


  388. PHILP L, Alimena S, Ferris W, Saini A, et al
    Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
    PubMed     Abstract available


  389. HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
    Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
    PubMed     Abstract available


  390. MONK BJ, Smith G, Lima J, Long GH, et al
    Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
    PubMed     Abstract available


  391. KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
    Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
    PubMed     Abstract available


  392. GUANI B, Mahiou K, Crestani A, Cibula D, et al
    Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01672.
    PubMed     Abstract available


  393. AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
    Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
    PubMed     Abstract available


  394. HA HI, Park EY, Eoh KJ, Lee YJ, et al
    Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
    PubMed     Abstract available


  395. DAVIDSON BA, Puechl AM, Watson CH, Lim S, et al
    Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers.
    Gynecol Oncol. 2021 Dec 15. pii: S0090-8258(21)01635.
    PubMed     Abstract available


  396. SWIFT BE, Maeda A, Bouchard-Fortier G
    Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
    PubMed     Abstract available


  397. SHI Y, Chen J, Shi B, Liu A, et al
    Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01633.
    PubMed     Abstract available


  398. ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
    Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
    PubMed     Abstract available


  399. DEBOER RJ, Umutoni V, Bazzett-Matabele L, Katznelson E, et al
    Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
    Gynecol Oncol. 2021 Dec 13. pii: S0090-8258(21)01628.
    PubMed     Abstract available


  400. SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
    Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
    PubMed     Abstract available


  401. MATULONIS UA, Huang HQ, Filiaci VL, Randall M, et al
    Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
    Gynecol Oncol. 2021 Dec 10. pii: S0090-8258(21)01625.
    PubMed     Abstract available


  402. NICA A, Sutradhar R, Kupets R, Covens A, et al
    Pre-operative wait times in high-grade non-endometrioid endometrial cancer: Do surgical delays impact patient survival?
    Gynecol Oncol. 2021 Dec 9. pii: S0090-8258(21)01621.
    PubMed     Abstract available


  403. LARA OD, Smith M, Wang Y, O'Cearbhaill RE, et al
    COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.
    Gynecol Oncol. 2021 Dec 7. pii: S0090-8258(21)01629.
    PubMed     Abstract available


  404. KORENAGA TK, Yoshida EJ, Pierson W, Chang J, et al
    Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
    Gynecol Oncol. 2021 Dec 2. pii: S0090-8258(21)01608.
    PubMed     Abstract available


  405. WEI JJ
    Linking altered microRNA expression to racial disparities in uterine serous carcinoma.
    Gynecol Oncol. 2021;163:446-447.
    PubMed    


  406. HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
    Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    Gynecol Oncol. 2021;163:563-568.
    PubMed     Abstract available


    November 2021
  407. JOHN CS, Fong A, Alban R, Gillen J, et al
    Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
    PubMed     Abstract available


  408. DOLL KM, Nguyen A, Alson JG
    A conceptual model of vulnerability to care delay among women at risk for endometrial cancer.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01603.
    PubMed     Abstract available


  409. DUPONT NC, Enserro D, Brady MF, Moxley K, et al
    Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
    PubMed     Abstract available


  410. MANZOUR N, Nunez-Cordoba JM, Chiva L, Chacon E, et al
    Pattern of relapse in patients with stage IB1 cervical cancer after radical hysterectomy as primary treatment. Minimally invasive surgery vs. open approach. Systematic review and meta-analysis.
    Gynecol Oncol. 2021 Nov 27. pii: S0090-8258(21)01623.
    PubMed     Abstract available


  411. MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
    Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
    PubMed     Abstract available


  412. CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
    Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
    PubMed     Abstract available


  413. ARYASOMAYAJULA C, Chanana A, Tandel M, Kwan L, et al
    The role of high-risk HPV testing in cervical cancer surveillance.
    Gynecol Oncol. 2021 Nov 23. pii: S0090-8258(21)01606.
    PubMed     Abstract available


  414. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
    Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
    PubMed    


  415. NJOKU K, Ramchander NC, Wan YL, Barr CE, et al
    Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.
    Gynecol Oncol. 2021 Nov 18. pii: S0090-8258(21)01602.
    PubMed     Abstract available


  416. MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
    Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
    PubMed     Abstract available


  417. HUANG J, Deng Y, Boakye D, Tin MS, et al
    Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01598.
    PubMed     Abstract available


  418. LADBURY C, Li R, Shiao J, Liu J, et al
    Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?
    Gynecol Oncol. 2021 Nov 15. pii: S0090-8258(21)01600.
    PubMed     Abstract available


  419. MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
    Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
    Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
    PubMed     Abstract available


  420. WEEKS KS, Lynch CF, West M, Carnahan R, et al
    Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
    PubMed     Abstract available


  421. KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
    Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
    PubMed     Abstract available


  422. FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
    Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
    PubMed     Abstract available


  423. PRAISS AM, Huang Y, St Clair CM, Melamed A, et al
    Long-term outcomes of vaginal hysterectomy for endometrial cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01526.
    PubMed     Abstract available


  424. SISODIA RC, Alimena S, Ferris W, Saini A, et al
    Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01528.
    PubMed     Abstract available


  425. MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
    Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
    PubMed     Abstract available


  426. ORELLANA TJ, Kim H, Beriwal S, Bhargava R, et al
    Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01515.
    PubMed     Abstract available


  427. MENG Y, Chu T, Lin S, Wu P, et al
    Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01451.
    PubMed     Abstract available


  428. ALHILLI MM, Arend RC
    International gynecologic cancer society (IGCS) 2021 meeting report.
    Gynecol Oncol. 2021 Nov 1. pii: S0090-8258(21)01548.
    PubMed    


  429. HINCHCLIFF EM, Westin SN
    Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls.
    Gynecol Oncol. 2021;163:217-219.
    PubMed    


  430. SACCARDI C, Zovato S, Spagnol G, Bonaldo G, et al
    Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Gynecol Oncol. 2021;163:364-370.
    PubMed     Abstract available


    October 2021
  431. MATSUO K, Klar M, Khetan VU, Violette CJ, et al
    Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States.
    Gynecol Oncol. 2021 Oct 30. pii: S0090-8258(21)01529.
    PubMed     Abstract available


  432. ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
    A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
    PubMed     Abstract available


  433. CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
    Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
    PubMed     Abstract available


  434. WARRING SK, Borah B, Moriarty J, Gullerud R, et al
    The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01523.
    PubMed     Abstract available


  435. GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
    Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
    PubMed     Abstract available


  436. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
    PubMed     Abstract available


  437. CHARGARI C, Arbyn M, Leary A, Abu-Rustum NR, et al
    Increasing global accessibility to high-level treatments for cervical cancers.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01517.
    PubMed     Abstract available


  438. SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
    Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
    Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
    PubMed     Abstract available


  439. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    PubMed     Abstract available


  440. WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
    Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
    PubMed     Abstract available


  441. BALAYA V, Guani B, Morice P, Querleu D, et al
    Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01518.
    PubMed     Abstract available


  442. SHIN W, Park SY, Seo SS, Lim MC, et al
    Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01514.
    PubMed     Abstract available


  443. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    PubMed     Abstract available


  444. GUDGEON JM, Wallentine JC, Bonham EM, McLaughlin HD, et al
    Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial.
    Gynecol Oncol. 2021 Oct 21. pii: S0090-8258(21)01401.
    PubMed     Abstract available


  445. HE WQ, Li C
    Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends.
    Gynecol Oncol. 2021 Oct 20. pii: S0090-8258(21)01519.
    PubMed     Abstract available


  446. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    PubMed    


  447. HOROWITZ NS, Eskander RN, Adelman MR, Burke W, et al
    Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01421.
    PubMed    


  448. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    PubMed     Abstract available


  449. MARTIN A, Wells A, Anderson ML, Chern JY, et al
    Trends in ureteral surgery on an academic gynecologic oncology service.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01453.
    PubMed     Abstract available


  450. THOMAIER L, Darst BF, Jewett P, Hoffmann C, et al
    Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01450.
    PubMed     Abstract available


  451. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
    Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].
    Gynecol Oncol. 2021 Oct 12. pii: S0090-8258(21)01386.
    PubMed    


  452. GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
    Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
    PubMed     Abstract available


  453. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    PubMed     Abstract available


  454. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    PubMed     Abstract available


  455. EDMONDSON RJ, O'Connell RL, Banerjee S, Mileshkin L, et al
    Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
    Gynecol Oncol. 2021 Oct 5. pii: S0090-8258(21)01379.
    PubMed     Abstract available


  456. SHAH PD, Wethington SL, Pagan C, Latif N, et al
    Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
    PubMed     Abstract available


  457. ALHILLI MM, Rybicki L, Carr C, Yao M, et al
    Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
    PubMed     Abstract available


  458. LEE L, Howitt B, Cheng T, King M, et al
    MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01384.
    PubMed     Abstract available


  459. TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
    Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
    PubMed    


  460. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.
    PubMed    


  461. VAN TRIEST B, Rasing M, van der Velden J, de Hullu J, et al
    Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study.
    Gynecol Oncol. 2021;163:117-124.
    PubMed     Abstract available


    September 2021
  462. SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
    Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
    PubMed     Abstract available


  463. AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
    Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
    PubMed     Abstract available


  464. HOEIJMAKERS YM, Eysbouts YK, Massuger LFAG, Dandis R, et al
    Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01385.
    PubMed     Abstract available


  465. LI JY, Park HS, Huang GS, Young MR, et al
    Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
    PubMed     Abstract available


  466. HA HI, Cho SH, Lim J, Lee YJ, et al
    Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
    PubMed     Abstract available


  467. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01393.
    PubMed    


  468. BRYK S, Katuwal S, Haltia UM, Tapper J, et al
    Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
    Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
    PubMed     Abstract available


  469. VAN DER PLAS RCJ, Bos AME, Jurgenliemk-Schulz IM, Gerestein CG, et al
    Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.
    Gynecol Oncol. 2021 Sep 25. pii: S0090-8258(21)01334.
    PubMed     Abstract available


  470. ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
    Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
    PubMed     Abstract available


  471. RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
    Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
    PubMed     Abstract available


  472. CONTOS G, Baca Y, Xiu J, Brown J, et al
    Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Gynecol Oncol. 2021 Sep 22. pii: S0090-8258(21)01380.
    PubMed     Abstract available


  473. JOU J, Charo L, Hom-Tedla M, Coakley K, et al
    Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01374.
    PubMed     Abstract available


  474. LEE SJ, Kim YH, Lee MY, Ko HS, et al
    Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
    PubMed     Abstract available


  475. AO M, Zheng D, Wang J, Gu X, et al
    Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia.
    Gynecol Oncol. 2021;162:584-589.
    PubMed     Abstract available


  476. GWACHAM NI, McKenzie ND, Fitzgerald ER, Ahmad S, et al
    Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives.
    Gynecol Oncol. 2021;162:809-815.
    PubMed     Abstract available


    August 2021
  477. SALANI R, Liu JF
    The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
    Gynecol Oncol. 2021;162:245-248.
    PubMed    


  478. GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
    FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
    Gynecol Oncol. 2021;162:413-420.
    PubMed     Abstract available


  479. KELTTO N, Leivonen A, Pankakoski M, Sarkeala T, et al
    Cervical testing beyond the screening target age - A register-based cohort study from Finland.
    Gynecol Oncol. 2021;162:315-321.
    PubMed     Abstract available


    July 2021
  480. CUZICK J, Du R, Adcock R, Kinney W, et al
    Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00525.
    PubMed     Abstract available


  481. SALVADO A, Miralpeix E, Sole-Sedeno JM, Kanjou N, et al
    Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping.
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00515.
    PubMed     Abstract available


    June 2021
  482. CHATZISTAMATIOU K, Tsertanidou A, Moysiadis T, Mouchtaropoulou E, et al
    Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
    Gynecol Oncol. 2021 Jun 28. pii: S0090-8258(21)00516.
    PubMed     Abstract available


  483. VAN KEER S, Peeters E, Vanden Broeck D, De Sutter P, et al
    Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00490.
    PubMed     Abstract available


  484. PEI X, Xiang L, Chen W, Jiang W, et al
    The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2021;161:779-786.
    PubMed     Abstract available


  485. CHIAPPA V, Interlenghi M, Salvatore C, Bertolina F, et al
    Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors.
    Gynecol Oncol. 2021;161:838-844.
    PubMed     Abstract available


  486. SEZEN D, Patel RR, Tang C, Onstad M, et al
    Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma.
    Gynecol Oncol. 2021;161:645-652.
    PubMed     Abstract available


  487. ZACH D, Avall-Lundqvist E, Falconer H, Hellman K, et al
    Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study.
    Gynecol Oncol. 2021;161:748-754.
    PubMed     Abstract available


    May 2021
  488. PRIESKE K, Woelber L, Muallem MZ, Eulenburg C, et al
    Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2021;161:442-448.
    PubMed     Abstract available


  489. BOHLIN KS, Bruno AK, von Knorring C, Rahm C, et al
    Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study.
    Gynecol Oncol. 2021;161:449-453.
    PubMed     Abstract available


  490. KOUAL M, Benoit L, Nguyen-Xuan HT, Bentivegna E, et al
    Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review.
    Gynecol Oncol. 2021;161:436-441.
    PubMed     Abstract available


  491. GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecol Oncol. 2021;161:512-515.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: